Premium
Maternal medication use and the risk of brain tumors in the offspring: The SEARCH international case‐control study
Author(s) -
Cardy Amanda H.,
Little Julian,
McKeanCowdin Roberta,
Lijinsky William,
Choi N. Won,
Cordier Sylvanie,
Filippini Graziella,
Holly Elizabeth A.,
Lubin Flora,
McCredie Margaret,
Mueller Beth A.,
PerisBonet Raphael,
Arslan Annie,
PrestonMartin Susan
Publication year - 2005
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.21482
Subject(s) - offspring , medicine , pregnancy , population , brain tumor , glioma , case control study , pediatrics , bioinformatics , pathology , environmental health , biology , cancer research , genetics
N ‐nitroso compounds (NOC) have been associated with carcinogenesis in a wide range of species, including humans. There is strong experimental data showing that nitrosamides (R 1 NNO·COR 2 ), a type of NOC, are potent neuro‐carcinogens when administered transplacentally. Some medications are a concentrated source of amides or amines, which in the presence of nitrites under normal acidic conditions of the stomach can form NOC. Therefore, these compounds, when ingested by women during pregnancy, may be important risk factors for tumors of the central nervous system in the offspring. The aim of the present study was to test the association between maternal use of medications that contain nitrosatable amines or amides and risk of primary childhood brain tumors (CBT). A case‐control study was conducted, which included 1,218 cases and 2,223 population controls, recruited from 9 centers across North America, Europe and Australia. Analysis was conducted for all participants combined, by tumor type (astroglial, primitive neuroectodermal tumors and other glioma), and by age at diagnosis (≤5 years; >5 years). There were no significant associations between maternal intake of medication containing nitrosatable amines or amides and CBT, for all participants combined and after stratification by age at diagnosis and histological subtype. This is the largest case‐control study of CBT and maternal medications to date. Our data provide little support for an association between maternal use of medications that may form NOC and subsequent development of CBT in the offspring. © 2005 Wiley‐Liss, Inc.